**RESEARCH HIGHLIGHT**

S-1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer

Feiyu Diao¹, Wei Lai² and Zhonghua Chu²*

---

**Main text**

Gastric cancer (GC) is the fourth most common cancer worldwide [1], with approximately 50% of GC cases and deaths occurring in China [2]. Gastrectomies have the potential to remove all visible tumor tissues and obtain histologically free-margins, which have shown to provide curative reliability in patients with early-stage GC [3, 4]. However, < 25% of GC cases are diagnosed with early-stage disease. The survival of the remaining patients falls below 50% [5], even though after undergoing D2 gastrectomy or acquired targeted therapy [6, 7]; thereby prompting more commitment in finding other alternatives in the hope of improving the patient outcomes. Results from two landmark trials in 2001 and 2006 have demonstrated that adjuvant therapies using post-operative chemoradiotherapy and perioperative chemotherapy (CT) were effective therapeutic options [8, 9]. Currently, both of them are accepted standards of care in the West.

Publication of landmark trial in 2007 (the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer) demonstrated that patients with stage II or III GC receiving 12-month of postoperative S-1 treatment could benefit from a significantly longer overall survival (OS) and relapse-free survival (RFS) as compared with those had surgical recession alone [10]. Recently, the adjuvant CT trial of capecitabine-oxaliplatin doublet for GC has demonstrated similar survival benefit [11]. Therefore, Chinese GC patients currently have two standard treatments with similar efficacy [12]. However, because of the poor outcome for stage III GC patients who undergo the S-1 monotherapy, better alternatives are being relentless researched [13]. A previous study has shown that docetaxel has efficacy in combination with S-1 [14]. But there is still no evidence regarding the safety and efficacy of S-1-docetaxel doublet in the treatment of stage III GC.

In a study recently published in *Journal of Clinical Oncology*, titled “Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial”, Yoshida et al. [15] conducted a randomized phase III study to investigate the superiority of postoperative S-1 plus docetaxel over S-1 alone for R0 resection of pathologic stage III GC.

In that study, the authors planned to enroll 1100 patients from April 2013 to December 2017 at 138 study sites in Japan. They conducted the second interim analysis in April 2017 when the number of events reached 216 among 915 enrolled patients. Of these cases, 341 patients have been treated with S-1 plus docetaxel and 348 treated with S-1 alone. The median follow-up time was 12.5 months. The baseline characteristics were well-balanced between the two groups. From the second interim analysis, the authors found that the 3-year RFS in the S-1 plus docetaxel group was 66% (95% confidence interval [CI] 59%–73%) as compared to 50% (95% CI 41%–58%) in the S-1 group; indicating that the RFS rate of S-1 plus docetaxel group was statistically higher than that of S-1 group (hazard ratio = 0.632; 99.99% CI 0.400–0.998; \( P < 0.001 \)). Therefore, the enrollment was prematurely terminated as recommended by the independent data and the safety monitoring committee. The adverse event analyses,
particularly for neutropenia and leukopenia, demonstrated that the incidences of grade 3 or greater adverse events were higher in the S-1 plus docetaxel group as compared to the S-1 group. Fortunately, all adverse events were manageable.

Since the era of comparisons with gastrectomy alone, no critical trials have been conducted to explore the advantages of more intensive postoperative CT over S-1 monotherapy, however, the present study has filled this gap. A previous study found that a combination of S-1 and cisplatin was poorly tolerated in the postoperative adjuvant CT for advanced GC in Japan [16]. Additionally, a phase III clinical trial comparing the efficacy of S-1 combination with docetaxel and S-1 monotherapy showed significant improvement in time to progression of advanced GC patients receiving S-1 plus docetaxel [17]. Furthermore, previous feasibility study has indicated that S-1 combination with docetaxel was well-tolerated after gastrectomy [18]. Thus, the combination of S-1 and docetaxel aroused the attentions of clinicians. In the present study, this regimen met the predetermined hypothesis for more than 15% improvement in 3-year RFS at the second interim analysis and the RFS benefit was accomplished by a favorable safety profile. These findings can be applicable in countries in which perioperative CT or chemoradiation is not standard.

The limitations of this study include: (1) the number of deaths at the time of the interim analysis was relatively small, thus, the OS data should be cautiously reconsidered; (2) the early termination of the study at the interim analysis; (3) The patient number at risk did not reach the desired number, which may further delimit the observed findings; and (4) the survival difference between the two groups may have been a result of the poor 3-year RFS of patients in the S-1 group, which was far lower than the pretrial estimation. Therefore, the tremendous research still needs to be done in the future, including but not limiting to, (1) conducting additional follow-up for future evaluation of secondary endpoints that include OS; (2) recalculate the sites of relapse at such endpoints.

Abbreviations
GC: gastric cancer; CT: chemotherapy; OS: overall survival; RFS: relapse-free survival; CI: confidence interval.

Acknowledgements
Not applicable.

Authors’ contributions
All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of General Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, P. R. China. 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong, P. R. China.

Received: 26 September 2019 Accepted: 11 October 2019
Published online: 26 October 2019

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
2. Gao K, Wu J. National trend of gastric cancer mortality in China (2003–2015): a population-based study. Cancer Commun. 2019;39(1):24. https://doi.org/10.1186/s40880-019-0372-x.
3. Weledji EP. The principles of the surgical management of gastric cancer. Int J Surg Oncol. 2017;2(7):e11. https://doi.org/10.1097/IJ9.000000000000017.
4. Fang C, Wang W, Deng JY, Sun Z, Seeruttun SR, Wang ZN, et al. Proposal and validation of a modified staging system to improve the prognosis predictive performance of the 8th AJCC/UICC pTNM staging system for gastric adenocarcinoma: a multicenter study with external validation. Cancer Commun. 2018;38(1):67. https://doi.org/10.1186/s40880-018-0344-6.
5. Strong VE, D’Amico TA, Kleinberg L, Ajani J. Impact of the 7th edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Cancer Netw. 2013;11(6):60–6.
6. Shen L. Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer. Cancer Commun. 2018;38(1):72. https://doi.org/10.1186/s40880-018-0344-6.
7. Wang W, Sun Z, Deng JY, Qi XL, Feng XY, Fang C, et al. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. Cancer Commun. 2018;38(1):23. https://doi.org/10.1186/s40880-018-0293-0.
8. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiation therapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med. 2001;345(10):725–30. https://doi.org/10.1056/NEJMoa010187.
9. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med. 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055331.
10. Sakuramoto S, Sasaki M, Yamaguchi T, Kinoshita T, Fuji M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New Engl J Med. 2007;357(18):1810–20. https://doi.org/10.1056/NEJMoa072252.
11. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21. https://doi.org/10.1016/S0140-6736(11)61873-4.
12. Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun. 2019;39(1):10. https://doi.org/10.1186/s40880-019-0349-9.
13. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93. https://doi.org/10.1200/JCO.2011.36.5908.

14. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006;12(11 Pt 1):3402–7. https://doi.org/10.1158/1078-0432.CCR-05-2425.

15. Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296–304. https://doi.org/10.1200/JCO.18.01138.

16. Koizumi W, Narakara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21. https://doi.org/10.1016/S1470-2045(08)70035-4.

17. Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140(2):319–28. https://doi.org/10.1007/s00432-013-1563-5.

18. Fujitani K, Tamura S, Kimura Y, Tsuji T, Matsuyama J, Iijima S, et al. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Gastric Cancer. 2014;17(2):348–53. https://doi.org/10.1007/s10120-013-0273-7.